BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
BioCentury | Sep 7, 2018
Company News

Amid launch troubles, Portola commercial chief Fu resigns

With its stock price near its 52-week low amid a disappointing launch of anticoagulant Bevyxxa betrixaban, Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said EVP and Chief Commercial and Business Officer Tao Fu is resigning to pursue other...
BioCentury | Aug 3, 2018
Clinical News

Amgen's Blincyto among negative CHMP opinions

EMA's CHMP released a handful of negative opinions July 27, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC...
BioCentury | Jul 27, 2018
Company News

New Blincyto indication among negative CHMP opinions

EMA's CHMP released a handful of negative opinions Friday, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC from...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
BioCentury | Mar 30, 2018
Clinical News

Negative CHMP opinion for Portal VTE candidate

EMA's CHMP recommended against approval of Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to prevent venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness with risk factors for VTE, including VTE-related death....
BioCentury | Mar 23, 2018
Company News

CHMP rebuffs Portola's betrixaban, Radius' abaloparatide-SC

EMA's CHMP issued negative opinions on Friday for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC from Radius Health Inc. (NASDAQ:RDUS). The committee recommended against approval of Dexxience to prevent venous thromboembolism (VTE)...
BioCentury | Feb 23, 2018
Clinical News

Portola expects CHMP to recommend andexanet alfa, but not betrixaban

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said EMA's CHMP communicated a "positive trend vote" for an MAA for AndexXa andexanet alfa (IndexXa, PRT4445, PRT064445) to reverse the anticoagulant effects of Factor Xa inhibitors. However, Portola said the...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
Items per page:
1 - 10 of 72